You are here: Industry Insights > mRNA

News List

Moderna receives emergency use listing from WHO for Covid-19 vaccine pharmaceutical-technology
May 06, 2021
Moderna has received emergency use listing (EUL) from the World Health Organization (WHO) for its Covid-19 vaccine to prevent the disease in individuals aged 18 years and above.
CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic worldpharmanews
April 26, 2021
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV ...
Sanofi Acquires Tidal Therapeutics contractpharma
April 13, 2021
Sanofi acquired Tidal Therapeutics, a preclinical stage biotech company with a novel mRNA-platform for reprogramming of immune cells, for $160 million upfront and up to $310 million in milestones.
Exacis Develops mRNA-Engineered iPSC-Derived NK Cells for Difficult-To-Treat Tumors americanpharmaceuticalreview
April 01, 2021
Exacis Biotherapeutics announced several steps in the preclinical development of its ExaNK™ engineered NK cell-therapy candidates.
CureVac, Celonic Enter COVID-19 Vax Mfg. Pact contractpharma
March 31, 2021
Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year at Heidelberg facility.
BioNTech Provides Update on Vaccine Production Status at Marburg Manufacturing Site americanpharmaceuticalreview
March 30, 2021
BioNTech announced the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part of the process, EMA has approved the production of the drug substance, the mRNA, at the Marburg ...
EMA Approves BioNTech's COVID Vax Production at Marburg Site contractpharma
March 29, 2021
Largest mRNA vaccine manufacturing site in Europe has annual production capacity of up to one billion doses of its COVID-19 vaccine.
Anima signs new strategic collaboration deal with Takeda pharmaceutical-business-review
March 22, 2021
Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate worldpharmanews
March 19, 2021
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2 ...
Maravai Expands CDMO Capabilities Through TriLink Biotechnologies contractpharma
March 16, 2021
Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, has expanded its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies with the launch of ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page